Hypomethylating Agents in the Treatment of Myelodysplastic Syndrome Anjali Advani, MD
•
Should New Results From ASH 2005 Alter Your Management of Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia? Andrew D. Zelenetz, MD, PhD; Heather Gatcombe, MD
•
Update on Targeted Therapy in Acute Myeloid Leukemia Richard M. Stone, MD
Unrelated Cord Blood Transplant Effective in ALL, AML12/16/05 [Medscape Medical News] Leukemia patients undergoing unrelated umbilical cord blood transplantation are 1.4 times more likely to achieve leukemia-free survival.
Regimen May Prevent Joint Damage in Hemophilia12/14/05 [Medscape Medical News] An aggressive regimen of factor VIII infusions every other day produced an 84% reduction in joint damage.
Novel Drug Effective Against Imatinib-Resistant Leukemia12/13/05 [Medscape Medical News] AMN107 was observed to be 10- to 50-fold more potent than imatinib against BCR-ABL expressing cell lines, including mutations that develop during treatment with imatinib, researchers report.
The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the American Society of Hematology. These materials and the related activity are not sanctioned by the American Society of Hematology or the commercial supporter of the conference, and do not constitute an official part of that conference.
The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.
